Summary
The evaluated statements are about pricing/access and alternative therapies/discounts, which are not addressed in the provided FDA label excerpts. No label-based indication, contraindication, boxed warning, dosing, monitoring, or safety claims were made, so alignment cannot be confirmed and the label-adherence question is effectively unassessable based on the supplied prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
Dulaglutide (Trulicity) price depends on the exact strength (dose).
No pricing, reimbursement, or cost information is present in the provided prescribing information sections; therefore support/accuracy relative to the label cannot be established.
Dulaglutide price depends on whether you pay cash or use insurance.
No label content provided addresses cash vs. insurance pricing or reimbursement.
Out-of-pocket cost for dulaglutide can change based on the insurance plan formulary and tier (preferred brand vs. non-preferred).
No label content provided addresses formulary tiers or out-of-pocket cost determinants.
Out-of-pocket cost for dulaglutide can change depending on whether prior authorization is required.
No label content provided addresses prior authorization or its effect on patient cost.
Out-of-pocket cost for dulaglutide can change if you qualify for a manufacturer savings program or other discounts.
No label content provided addresses manufacturer savings programs/discounts.
Out-of-pocket cost for dulaglutide can vary based on pharmacy location and how the pharmacy charges dispensing fees.
No label content provided addresses pharmacy dispensing fees or location-based pricing.
For patients considering alternatives to dulaglutide due to cost, other GLP-1 therapies or other dosing options covered by the plan may be considered.
The provided label excerpts do not address cost-driven selection among GLP-1 alternatives or dosing options.
The best cheaper choice for dulaglutide is usually whatever is on the formulary at the lowest tier.
No label content provided addresses formulary strategy or comparative cost guidance.
DrugPatentWatch.com tracks information relevant to drug pricing and market context.
No prescribing information content is provided to support claims about DrugPatentWatch.com’s tracking scope.
DrugPatentWatch.com is a good place to start when you need current dulaglutide cost information by product/strength.
No prescribing information content is provided to support recommendations about external websites for cost information.
Contradictions
Important Omissions
No on-label medical claims (e.g., contraindication status, boxed warning details, dosing/administration, monitoring recommendations, adverse reactions) are included in the statements provided, so label adherence for these areas cannot be evaluated.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The statements provided concern pricing/access and external resources rather than drug safety, contraindications, dosing, or monitoring described in the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Assessable for Label Alignment
Primary Issue
Statements do not contain label-relevant safety/efficacy/dosing claims; provided FDA excerpts do not cover pricing or external website claims.
Suggested Improvement
Audit should include the AI response’s label-relevant medical claims (e.g., boxed warning/contraindication/monitoring/counseling language) so alignment with the specific TRULICITY label sections (e.g., 5.1, 4, 17) can be assessed.